Navigation Links
Gene Variant Could Lower Alzheimer's Risk
Date:1/12/2010

Carrying two 'good' copies slows age-linked mental decline by half, study found

TUESDAY, Jan. 12 (HealthDay News) -- A gene variant that is good for the heart also appears to be good for the brain, slowing age-related decline in mental function and cutting the odds for Alzheimer's disease, a study indicates.

"If you carry two copies of the favorable form of the gene, it reduces the risk of Alzheimer's disease by 70 percent," explained study lead author Dr. Richard B. Lipton, professor and vice chair of neurology at Albert Einstein College of Medicine in New York City.

Drugs that mimic the activity of the gene variant already are being developed, said Lipton, whose group reported the finding in the Jan. 13 issue of the Journal of the American Medical Association.

A 2003 study by Lipton and his associates identified a variant of the gene for cholesterol ester transfer protein (CETP) -- involved in carrying cholesterol in the bloodstream -- as being associated with a longer life span. "The longer you live, the more common is the favorable variant," Lipton noted. "The incidence is 5 percent at age 50 and 35 percent at age 95."

The new study followed 523 people, all age 70 or older, for four years, testing their mental function and relating it to the variant of the CETP gene they carried.

Participants who carried two copies of the variant gene experienced an age-related decline in mental function that was about half as rapid as people with two normal versions of the gene, the study found.

Individuals with two copies of the favorable CETP variant also had a reduced risk of developing Alzheimer's disease compared to those with two normal versions of the gene, the study found.

Besides its effects on the brain, the favorable CETP gene variant also appears to boost blood levels of HDL ("good") cholesterol, which helps prevent artery-blocking clots from forming.

How does the gene variant work its magic? Lipton put forth two theories.

"We know that it protects against disease in blood vessels," he said. "It lowers the risk of heart attack and stroke, and stroke is a risk factor for cognitive decline. So it protects the brain against atherosclerotic disease.

"The other mechanism is more speculative. It might protect against formation of proteins involved in Alzheimer's disease, such as beta-amyloid," Lipton said. The buildup of beta-amyloid protein plaques within brain tissue has long been a hallmark of Alzheimer's disease.

One expert found the study results intriguing.

"It's a great candidate gene for research on Alzheimer's disease and dementia," said Dr. James Burke, director of the Memory Disorders Clinic at Duke University Medical Center in Durham, N.C.

The benefit probably does not come from improved blood flow to the brain, he said. "I think it's related to lipid-cholesterol transport and metabolism," Burke said. Drugs that raise HDL level in the same way as the variant gene might therefore be useful against Alzheimer's disease, he reasoned.

According to the researchers, the CETP gene variant was first identified in a population of Ashkenazi Jews, descendents of western and central Europeans. The current study was done among an ethnically diverse population of people living in the Bronx who have been followed for 25 years.

It remains a small study that requires verification in broader research, Lipton said. "We have enrolled 600 additional people who we are following and we hope to enroll other groups," he noted.

Most studies of the genetics of Alzheimer's disease have concentrated on genes associated with increased risk, such as the ApoE-a4 gene, which also is involved in cholesterol metabolism, Lipton pointed out. "We hope that by understanding the genetics of the condition we can improve diagnosis or treatment or both," he said.

More information

There's more on Alzheimer's disease at the Alzheimer's Association.



SOURCES: Richard B. Lipton, M.D., professor, vice chair, neurology, Albert Einstein College of Medicine, New York City; James Burke, M.D, Ph.D., director, Memory Disorders Clinic, Duke University Medical Center, Durham, N.C; Jan. 13, 2010 Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Genetic variant associated with aggressive form of prostate cancer
2. Gene Variant Seems to Guard Against Asthma, COPD
3. Five Gene Variants May Be Linked to Lung Disease
4. Genetic Variant Slows AIDS Progression
5. Gene Variants Behind Vulnerability to Yeast Infections
6. Clues to visual variant Alzheimers; myopia and diabetic retinopathy risk
7. Glaucoma Tied to Gene Variants in Blacks
8. Trio of Gene Variants Discovered That May Raise Alzheimers Risk
9. Variants of umami taste receptor contribute to our individualized flavor worlds
10. International Collaboration led by Dr. Pablo V. Gejman,Researcher At NorthShore University HealthSystem's Research Institute, Finds Genetic Association of Schizophrenia to Chromosome 6p Variant
11. Worlds largest DNA scan for autism uncovers new gene variant for disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: